iNGENū

Psyence Partners with iNGENū for Palliative Care Clinical Trial Life sciences biotech company Psyence Group Inc (OTCQB: PSYGF)’s wholly-owned Australian subsidiary Psyence Australia Pty Ltd. partnered with Contract Research Organization (CRO) iNGENū Pty Ltd to conduct a Phase 2b clinical...

Psycheceutical Bioscience (OTCPK: BWVI) is advancing its proprietary ketamine topical formulation into clinical studies. The life sciences company has partnered with Australian-based contract research organization iNGENū Pty Ltd.  The exclusive agreement is set to design and conduct two Phase...

Psychedelics biopharma company Lobe Sciences Ltd. (OTCQB: LOBEF) signed a deal with Cantheon Capital, a development of cannabinoids and psychedelic drugs supporter, for aggregate proceeds to the company of up to $1.5 million for an annual term with a 15% interest. Funding for...

Life sciences company Lobe Sciences Ltd. (OTCQB: LOBEF) and Australian contract research organization iNGENū Pty Ltd. have agreed to design and conduct three or more clinical studies testing Lobe's psilocin analogs, L-130 or L-131, under exclusive terms. iNGENū works on a global scale,...

Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) has entered into a research and development agreement with Cannvalate Pty Ltd for the initiation of the REBORN, PLENITUDE and CAUMZ clinical trials in Australia, and a subscription agreement contemplating a private placement of common shares...